Twist Bioscience Lilly TuneLab Antibody Data Deal
Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026
The agreement strengthens Altor BioScience's positioning in AI-enabled drug discovery services, potentially expanding its customer base and recurring data-service revenue, which is modestly positive for TWST shares. For Eli Lilly, the deal broadens the TuneLab ecosystem and data contributions, reinforcing its AI drug discovery leadership with limited near-term financial impact.
Altor BioScience Corporation announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the agreement, Twist will provide antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly proprietary research data. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this agreement, users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data, connecting experimental data with AI-enabled discovery to potentially accelerate antibody drug discovery. Twist states it produces antibodies with an industrial capacity of over 6,000 IgGs per week, with turnaround times starting at 10 business days for HEK293 expression and 13 business days for CHO expression, and delivers characterization data in as few as 15 business days. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D. TuneLab is hosted by Rhino Federated Computing, a third-party software company whose federated learning platform is built on Nvidia NV FLARE framework. Emily M. Leproust, CEO and co-founder of Altor BioScience, said the quality of an AI model output depends on the quality of the data used to train it. Daniel Skovronsky, Lilly chief scientific officer, said Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. Nisha Nanda, group vice president and head of Lilly Catalyze360, said most small biotechs lack access to the large-scale, high-quality data needed to train effective models.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard